<unk> <unk> <unk>  is the highest approved dose for this drug and it is estimated that approximately 2.1 million patients in the U.S. were prescribed this dose in the year 2010. In March 2010,<unk>  revised the<unk>  label and recommended that patients of Chinese descent should not receive<unk> <unk> <unk>  with cholesterol-modifying doses of niacin-containing product. This review was based on the interim results of Heart Protection Study. On 8th June 2011,<unk>  added another<unk> <unk><unk>  to the<unk>  of high dose<unk> . Based on the review of randomized clinical trial, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH),<unk>  recommended limiting the<unk>  of high-dose<unk> . This trial showed a significantly increased risk of myopathic complications (0.9% in intensive statin arm vs. 0.03% in standard dose arm) in the patients treated with<unk> <unk> <unk>  as compared to 20<unk>  dose.
FDA black box warning on the use of 80 mg simvastatin
PCI in the patient at risk of bleeding
Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for lipid management
Chronic stable angina guidelines for pharmacotherapy to improve prognosis and reduce symptoms
Chronic stable angina revascularization drug eluting stents
Chronic stable angina ACC/AHA guidelines for alternative therapies in patients with refractory angina
Chronic stable angina treatment angiotensin converting enzyme inhibitors 
Chronic stable angina treatment dipyridamole